Investigating the effects of specific tumor markers in lung cancer treatment
Official title: HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
Funded at University of California Los Angeles · NIH-10894083 · Data updated 2026-11-12
This study is looking at how certain genetic markers in people with non-small cell lung cancer might affect their response to a type of immunotherapy called PD-1 inhibitors, so we can better understand which patients could benefit the most from this treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $592,352 |
| NIH project number | 5R01CA276917-02 |
| Project ID | NIH-10894083 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have specific HLA-B44 genetic markers.
✕Less likely to help
Patients without non-small cell lung cancer or those who do not have the HLA-B44 alleles may not benefit from this research.
What this research studies
This research focuses on understanding how certain genetic markers, known as motif neoepitopes, affect the tumor microenvironment in patients with non-small cell lung cancer (NSCLC). By analyzing tumor samples from patients with specific HLA-B44 alleles, the study aims to uncover how these markers influence the effectiveness of PD-1 inhibitors, a type of immunotherapy. The research will utilize advanced techniques such as gene expression profiling and multiplex immunofluorescence to evaluate the immune response and cellular composition in tumors. This comprehensive approach seeks to identify which patients may benefit most from these treatments.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for lung cancer patients, improving their chances of durable responses to therapy.
How similar studies have gone: Previous research has shown promising results in understanding the role of genetic markers in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Garon, Edward B — University of California Los Angeles
- Study coordinator: Garon, Edward B
Related research
Other NIH-funded projects on the same topics.
-
HLA-B44 motif neoepitopes in NSCLC and how they affect the tumor environment
This grant studies how specific tumor mutations and HLA-B44 genetic patterns influence response to PD-1 inhibitors in non-small cell lung cancer, with the goal of better predicting who benefits from immunotherapy.
-
Using HLA-B44 tumor markers to predict lasting benefit from PD-1 therapy in lung cancer
This project looks at whether specific tumor changes tied to the HLA-B44 gene can help predict which non-small cell lung cancer patients will have long-lasting responses to PD-1 immunotherapy, with or without chemotherapy.
-
HLA-B44 genetic markers to predict long-term benefit from PD-1 immunotherapy in lung cancer
This project looks at whether certain HLA-B44-related tumor changes can help predict which people with non-small cell lung cancer will get lasting benefit from PD‑1 immunotherapy with or without chemotherapy.
-
Investigating how specific tumor markers affect lung cancer treatment responses
This study is looking at how certain genetic markers in lung cancer tumors might affect how well a specific immunotherapy works, and it's for patients with non-small cell lung cancer who have a certain genetic type, helping to find more personalized treatment options for them.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.